MedTrace Logo

A Clinical Trial of A Quadrivalent Influenza Vaccine

NCT03744104 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2688

Last updated 2024-01-02

No results posted yet for this study

Summary

The aim of this study is to assess the immunogenicity and safety of a quadrivalent influenza vaccine compared with a trivalent influenza vaccine in participants aged above 3 years.

Conditions

Interventions

BIOLOGICAL

Quadrivalent influenza vaccine

0.5 mL, intramuscular, one dose

BIOLOGICAL

Trivalent influenza vaccine A

0.5 mL, intramuscular, one dose

BIOLOGICAL

Trivalent influenza vaccine B

0.5 mL, intramuscular, one dose

Sponsors & Collaborators

  • Shanghai Institute Of Biological Products

    lead INDUSTRY

Principal Investigators

  • Hu Yuemei, PhD · Jiangsu Province Centers for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-11
Primary Completion
2019-10-08
Completion
2019-10-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03744104 on ClinicalTrials.gov